ACY-1215 - CAS 1316214-52-4

ACY-1215 (CAT: I001219) is a selective inhibitor of histone deacetylase 6 (HDAC6). By selectively targeting HDAC6, ACY-1215 modulates the acetylation of both histone and non-histone proteins, leading to various cellular effects. ACY-1215 has demonstrated promising anticancer activity by inhibiting the growth of cancer cells, inducing cell cycle arrest, promoting apoptosis, and inhibiting angiogenesis. It has shown particular efficacy in hematological malignancies, including multiple myeloma. ACY-1215’s specificity for HDAC6 inhibition and its favorable toxicity profile make it a potential therapeutic option for the treatment of cancer and other diseases associated with dysregulated protein acetylation.

Catalog Number: I001219

CAS Number: 1316214-52-4

PubChem Substance ID:355039829

Molecular Formula: C₂₄H₂₇N₅O₃

Molecular Weight:433.5

Purity: 98.0%

Appearance:white to off-white solid powder

* For research use only. Not for human or veterinary use.


SynonymsACY-1215; ACY1215; ACY 1215; N-[7-(hydroxyamino)-7-oxoheptyl]-2-(N-phenylanilino)pyrimidine-5-carboxamide


Molecular Formula: C₂₄H₂₇N₅O₃
Molecular Weight433.5
SolubilityDMSO 85 mg/ml; Water <1 mg/ml
StorageStore at -20°C
Overview of Clinical ResearchOriginator: Dana-Farber Cancer Institute; Harvard University<br /> Developer: Columbia University; Dana-Farber Cancer Institute; Massachusetts General Hospital; Regenacy Pharmaceuticals; University of Texas M. D. Anderson Cancer Center<br /> Class: Amides; Antineoplastics; Hydroxamic acids; Pyrimidines; Small molecules<br /> Mechanism of Action: HDAC6 protein inhibitors<br /> Orphan Drug Status: No<br /> New Molecular Entity: Yes<br />
IC505 nM

Computed Descriptor